Characterization of a new degradation product of nifedipine formed on catalysis by atenolol: A typical case of alteration of degradation pathway of one drug by another

Journal of Pharmaceutical and Biomedical Analysis

Volumn 89, Issue , 2014, Pages 6-17

  Handa, Tarun ^a   Singh, Saranjit ^a   Singh, Inder Pal ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Characterization; Degradation product; Fixed dose combination (FDC); Interaction; Nifedipine and atenolol

Indexed keywords

ACETAMIDE; AMIDE; ATENOLOL; CARBOXYLIC ACID; HYDROXYLAMINE; NIFEDIPINE;

AROMATIZATION; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CATALYSIS; DRUG DEGRADATION; DRUG HYDROLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; INFRARED SPECTROSCOPY; MOLECULAR INTERACTION; PHOTODEGRADATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; ULTRAVIOLET SPECTROSCOPY;

CHARACTERIZATION; DEGRADATION PRODUCT; FIXED-DOSE COMBINATION (FDC); INTERACTION; NIFEDIPINE AND ATENOLOL;

ADRENERGIC BETA-ANTAGONISTS; ATENOLOL; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMBINATIONS; DRUG INTERACTIONS; NIFEDIPINE; PHOTOLYSIS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84887897383     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.10.024     Document Type: Article

References (23)

1. Kumar V., Prasad B., Singh S. Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases. Drug Discov. Today: Ther. Strateg. 2008, 5:63-71.
2. Available from: [accessed 12.08.13]. http://www.fda.gov/Drugs/DrugSafety/DrugRecalls/default.htm.
3. Singh S., Mariappan T.T., Sharda N., Kumar S., Chakraborti A.K. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm. Pharmacol. Commun. 2000, 6:405-410.
4. Bhutani H., Singh S., Jindal K.C., Chakraborti A.K. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs. J. Pharm. Biomed. Anal. 2005, 39:892-899.
5. Kumar V., Malik S., Singh S. Polypill for the treatment of cardiovascular diseases Part 2. LC-MS/TOF characterization of interaction/degradation products of atenolol/lisinopril and aspirin, and mechanisms of formation thereof. J. Pharm. Biomed. Anal. 2008, 48:619-628.
6. Kumar V., Shah R.P., Singh S. LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases Part 1. Separation of active components and classification of their interaction/degradation products. J. Pharm. Biomed. Anal. 2008, 47:508-515.
7. Anderton J.L., Vallance B.D., Stanley N.N., Crowe P.F., Mittra B., Perks W.H. Atenolol and sustained release nifedipine alone and in combination in hypertension A randomised, double-blind, crossover study. Drugs 1988, 35:22-26.
8. Maclean D., Mitchell E.T., Coulson R.R., Fitzsimons T.J., McDevitt D.G. Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability. Br. J. Clin. Pharmacol. 1988, 25:425-431.
9. Stanley N.N., Thirkettle J.L., Varma M.P., Larkin H., Heath I.D. Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension. Drugs 1988, 35:29-35.
10. Iglesias R., Taboada C., Souto C., Martínez-Pacheco R., Gómez-Amoza J.L., Concheiro A. Nifedipine/atenolol interactions in gastrointestinal absorption and biotransformation. Pharmazie 1997, 52:717-720.
11. Matsuda Y., Teraoka R., Sugimoto I. Comparative evaluation of photostability of solid-state nifedipine under ordinary and intensive light irradiation conditions. Int. J. Pharm. 1989, 54:211-221.
12. Ohkubo T., Noro H., Sugawara K. High-performance liquid chromatographic determination of nifedipine and a trace photodegradation product in hospital prescriptions. J. Pharm. Biomed. Anal. 1992, 10:67-70.
13. Shim S.C., Pae A.N., Lee Y.J. Mechanistic studies on the photodegradation of nifedipine. Bull. Korean Chem. Soc. 1988, 9:271-274.
14. Hayase N., Itagaki Y.-I., Ogawa S., Akutsu S., Inagaki S.-I., Abiko Y. Newly discovered photodegradation products of nifedipine in hospital prescriptions. J. Pharm. Sci. 1994, 83:532-538.
15. Krzek J., Kwiecień A., Żylewski M. Stability of atenolol, acebutolol and propranolol in acidic environment depending on its diversified polarity. Pharm. Dev. Technol. 2006, 11:409-416.
16. 2 surface by high-performance liquid chromatography/high-resolution mass spectrometry. Rapid Commun. Mass Spectrom. 2008, 22:301-313.
17. ICH Photostability testing of new drug substances and products Q1B. International Conferences on Harmonisation 1996.
18. Infra-red Spectra for Reference in: Indian Pharmacopoeia 2010, vol. I:382. The Indian Pharmacopoeial Commission, Government of India, Ministry of Health and Family Welfare, Ghaziabad, India. 6th Ed.
19. Zega A., Srčič S., Mavri J., Bešter-Rogač M. Molecular interactions of 1,4-dihydropyridine derivatives with selected organic solvents: A volumetric, spectroscopic and computational study. J. Mol. Struct. 2008, 875:354-363.
20. 13C NMR and crystallographic evidence of push-pull effects in furoindolic β-enamino esters. Can. J. Chem. 1999, 77:130-137.
21. Ueyama E., Takahashi F., Ohashi J., Konse T., Kishi N., Kano K. Mechanistic study on degradation of azelnidipine solution under radical initiator-based oxidative conditions. J. Pharm. Biomed. Anal. 2012, 61:277-283.
22. ICH Impurities in new drugs substances Q3A(R2). International Conference on Harmonisation 2006.
23. US FDA ANDAs Impurities in Drug Products, Food and Drug Administration 2010, Silver Spring, MD, USA.